Day Two

• Aging and Muscle Loss as a Critical Challenge: Sarcopenia and age-related muscle dysfunction are major drivers of frailty, metabolic decline, and loss of independence in older adults
• Targeting Muscle Biology with BLX-0871: Biolexis’ isoform-selective AMPK activator, BLX-0871, uniquely stimulates glucose uptake and boosts muscle metabolism, counteracting muscle wasting and metabolic deterioration during aging
• Expanding the Role of GLP-1 with BLX-7006: Our novel oral GLP-1 receptor agonist, BLX-7006, provides weight loss and metabolic benefits while avoiding injection-related barriers to patient adoption.
• A New Paradigm for Healthy Aging: The combination of BLX-0871 and BLX-7006 offers a synergistic approach: driving weight loss, preserving lean muscle mass, and addressing age-related diseases by restoring metabolic resilience

• Understanding the biological drivers of sarcopenia in aging and chronic disease including muscle atrophy
• Designing clinical trials with muscle strength and mobility as primary outcomes to assess patient quality of life
• Exploring anabolic, hormonal, and regenerative approaches to restore muscle mass

• Presenting evidence linking thymic involution to increased incidence of cancer, infection and autoimmunity, leading to shortened lifespan
• Discussing potential pharmacological interventions to preserve thymic function and delay immune aging
• Introducing allogeneic iPSC-derived thymic implants to restore T cell immune education and a diverse repertoire
• Presenting preclinical data on thymus-targeted therapies

This 45-minute Roundtable will explore how using combination strategies in aging biology is creating new therapeutic leverage. Aging is multifactorial, and single agents often hit only one hallmark; combinations (small molecules, biologics, senolytics + immunomodulators, etc.) offer synergy, but also complexity. The discussion will focus on how to rationally design, validate, and translate combination regimens in aging and age-related disease fields.

• Exploring synergies between senotherapeutics, metabolic modulators, and immunetargeted agents
• Repurposing existing drugs alongside novel therapies to boost impact
• Rethinking dosing, timing, and safety frameworks for older populations
• Defining translational and regulatory pathways for combination therapies in aging

• End-to-End Drug Discovery: PSI unifies generative design, predictive modeling, and automated experimentation to accelerate the full drug discovery cycle, from targets to therapies
• Data-Driven Insights: By integrating omics, clinical, and real-world datasets, PSI uncovers mechanisms of aging and prioritizes interventions that extend healthspan
• Faster Translation: PSI compresses timelines and reduces costs by enabling rapid validation and testing of geroprotectors and longevity drugs
• Collaborative Research Partner: Designed as more than a tool, PSI empowers scientists to simulate interventions, explore hypotheses, and drive breakthroughs in aging therapeutics

• Exploring investor appetite for longevity-focused startups and clinical programs
• Defining inflection points from IND filing to proof-of-mechanism readouts to guide investment timing
• Highlighting de-risking strategies through biomarkers, partnerships, and AI platforms to improve predictability

• Translation of aging biology insights into therapeutic programs: navigating from analysis of longitudinal human aging datasets to clinical development while balancing innovation with feasibility
• Adapting to evolving markets and science: how data-driven decision making and enabled indication prioritization in response to emerging opportunities in metabolic disease
• Achieving product-market fit in the longevity space: demonstrating commercial viability through pharma partnerships and investor validation